AU2013337341B2 - Bremelanotide therapy for female sexual dysfunction - Google Patents

Bremelanotide therapy for female sexual dysfunction Download PDF

Info

Publication number
AU2013337341B2
AU2013337341B2 AU2013337341A AU2013337341A AU2013337341B2 AU 2013337341 B2 AU2013337341 B2 AU 2013337341B2 AU 2013337341 A AU2013337341 A AU 2013337341A AU 2013337341 A AU2013337341 A AU 2013337341A AU 2013337341 B2 AU2013337341 B2 AU 2013337341B2
Authority
AU
Australia
Prior art keywords
bremelanotide
pct
administration
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013337341A
Other languages
English (en)
Other versions
AU2013337341A1 (en
Inventor
Jeffrey D. Edelson
Robert Jordan
Carl Spana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosette Pharmaceuticals Inc
Original Assignee
Cosette Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013337341(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosette Pharmaceuticals Inc filed Critical Cosette Pharmaceuticals Inc
Publication of AU2013337341A1 publication Critical patent/AU2013337341A1/en
Application granted granted Critical
Publication of AU2013337341B2 publication Critical patent/AU2013337341B2/en
Assigned to COSETTE PHARMACEUTICALS, INC. reassignment COSETTE PHARMACEUTICALS, INC. Request for Assignment Assignors: PALATIN TECHNOLOGIES, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
AU2013337341A 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction Active AU2013337341B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US61/722,511 2012-11-05
US201361770535P 2013-02-28 2013-02-28
US61/770,535 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
AU2013337341A1 AU2013337341A1 (en) 2015-05-07
AU2013337341B2 true AU2013337341B2 (en) 2018-02-22

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013337341A Active AU2013337341B2 (en) 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN117860866A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (1) GEP20196947B (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915A1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60112440T2 (de) * 2000-05-31 2006-04-20 Novo Nordisk A/S Wegwerfbare zweispitzige injektionsnadel
MX2007006973A (es) * 2004-12-09 2007-08-15 West Pharm Serv Inc Acoplamiento para un dispositivo de auto-inyeccion.
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
CA2727317C (en) * 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
EP2501225B1 (en) * 2009-11-16 2017-11-01 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
AU2011242602B2 (en) * 2010-04-21 2015-06-18 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
UA118656C2 (uk) 2019-02-25
PH12015500915B1 (en) 2015-06-29
US20240335502A1 (en) 2024-10-10
US20180085425A1 (en) 2018-03-29
MX362610B (es) 2019-01-28
EP2916856B2 (en) 2023-10-18
SG11201502949QA (en) 2015-06-29
ES2701444T3 (es) 2019-02-22
EP2916856B1 (en) 2018-09-19
ES2701444T5 (es) 2024-05-21
US9700592B2 (en) 2017-07-11
NZ707246A (en) 2019-03-29
FI2916856T4 (fi) 2024-01-15
DK2916856T4 (da) 2024-01-22
ZA201503128B (en) 2016-11-30
BR112015009936A8 (pt) 2019-09-17
GEP20196947B (en) 2019-02-11
IL238276B (en) 2020-04-30
AU2013337341A1 (en) 2015-05-07
JP6567971B2 (ja) 2019-08-28
US20190216888A1 (en) 2019-07-18
EA032959B1 (ru) 2019-08-30
US20140378392A1 (en) 2014-12-25
CA2890081A1 (en) 2014-05-08
WO2014071339A3 (en) 2014-06-12
US9352013B2 (en) 2016-05-31
EP2916856A4 (en) 2016-06-22
JP2016503406A (ja) 2016-02-04
MX2015005486A (es) 2015-11-13
KR20150081345A (ko) 2015-07-13
US20210060120A1 (en) 2021-03-04
IL238276A0 (en) 2015-06-30
US10286034B2 (en) 2019-05-14
PH12015500915A1 (en) 2015-06-29
KR102253526B1 (ko) 2021-05-18
EP2916856A2 (en) 2015-09-16
DK2916856T3 (en) 2019-01-14
EA032959B9 (ru) 2019-11-27
PL2916856T5 (pl) 2024-01-29
BR112015009936A2 (pt) 2017-07-11
CN104755094A (zh) 2015-07-01
EA201590760A1 (ru) 2015-10-30
CN117860866A (zh) 2024-04-12
PL2916856T3 (pl) 2019-02-28
WO2014071339A2 (en) 2014-05-08
US20150231196A1 (en) 2015-08-20
US20220362328A1 (en) 2022-11-17
HK1211227A1 (en) 2016-05-20
MY179755A (en) 2020-11-12

Similar Documents

Publication Publication Date Title
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
Heaton et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men
SK145897A3 (en) Methods and formulations for modulating the human sexual response
US20140221497A1 (en) Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
CN109528626A (zh) 鼻内较低剂量强度睾酮凝胶制剂及其用于治疗性快感缺失病或性欲减退疾患的应用
US20240335502A1 (en) Uses of bremelanotide in therapy for female sexual dysfunction
WO2022115576A9 (en) Treatment of raynaud's disease
US12171807B2 (en) Use of bremelanotide in patients with controlled hypertension
CA2890081C (en) Uses of bremelanotide in therapy for female sexual dysfunction
WO2024146892A1 (en) Compound for treatment of erectile dysfunction
Duphorn TESTOSTERONE REPLACEMENT THERAPY IN LATE ONSET HYPOGONADISM

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20 MAR 2013 TO 20 NOV 2013 IN WHICH TO MEET THE REQUIREMENT OF THE GRACE PERIOD HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO MEET THE REQUIREMENT OF THE GRACE PERIOD HAS BEEN EXTENDED TO 20 NOV 2013

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: COSETTE PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): PALATIN TECHNOLOGIES, INC.